- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Intravaginal Ring Shows Promise for HIV Prevention
Novel delivery system is adaptable to almost any drug (Oct. 16)
The American Association of Pharmaceutical Scientists (AAPS) reports that a new intravaginal ring has been developed that allows 90-day intravaginal delivery of tenofovir (Viread, Gilead Sciences). Tenofovir is the only topical prophylactic that has been shown to be effective at reducing the sexual transmission of human immunodeficiency virus (HIV) when formulated in a short-lasting gel.
Information on the new device will be presented at the 2012 AAPS Annual Meeting and Exposition, which is being held October 14–18 in Chicago, Ill.
The AAPS reported that researchers at the University of Utah have created a reservoir ring partly composed of plastic tubing that absorbs water when placed in the body. Conventional ring technology, developed in the 1970s, is inadequate in delivering water-soluble drugs, such as tenofovir, the AAPS said. The new ring design allows tenofovir to be delivered for up to 90 days at doses expected to prevent HIV infection.
According to the researchers, the ring is adaptable to almost any drug.
Source: AAPS, October 16, 2012.